Navigation Links
Cancer Patients in Bangladesh Gain Access to Advanced RapidArc Radiotherapy Treatments from Varian Medical Systems
Date:2/7/2011

DHAKA, Bangladesh, Feb. 7, 2011 /PRNewswire/ -- Cancer patients in Bangladesh, a country of 160 million people served by just 11 modern radiotherapy linear accelerators, now have access to advanced radiotherapy technology from Varian Medical Systems (NYSE: VAR). Treatments using fast and efficient RapidArc® technology with respiratory gating have started on a new Clinac® iX medical linear accelerator at the new United Hospital Comprehensive Cancer Care Centre in the capital, Dhaka.  

"As well as offering great precision and excellent dose distribution, RapidArc enables us to deliver the dose more quickly," says Dr. Ayan Basu, M.D., head of radiation oncology at United Hospital, which is Bangledesh's first comprehensive cancer center. "This is a country with long waiting lists for treatment, so RapidArc will help us to treat many patients with advanced radiotherapy techniques. We are delighted to be the first hospital in the country to provide RapidArc for the benefit of our patients."

Doctors at United Hospital have begun delivering RapidArc on prostate and head/neck cancer patients. The advanced RapidArc system delivers precise image-guided IMRT (intensity modulated radiotherapy) up to four times faster than conventional IMRT. The RapidArc IMRT beam quickly delivers the dose while continuously rotating around the patient. Studies* show that faster treatments allow for greater precision, since there is less chance of patient or tumor movement during treatment delivery and, with less time on the treatment couch, also allow for greater patient comfort.

Dr. Basu said RapidArc is being used initially to treat cancers such as prostate, cervical and anal canal, and will also be used for stereotactic body radiotherapy treatments, which involve the use of very high-dose beams to quickly attack certain types of tumors in areas like the lung, liver, or spine.

The RapidArc-equipped Clinac device, ordered in June and installed in December, is the first treatment machine at the new facility. Two additional radiotherapy rooms have been constructed to allow for future expansion. United Hospital has acquired the first PET-CT and cyclotron in Bangladesh and also offers treatments using a Varian GammaMed® HDR (high dose rate) brachytherapy afterloader.

United Hospital is a private, 450-bed multi-disciplinary hospital designated as a referral hospital by the Bangladesh government. It is situated on the lakeside area in Gulshan, a premier diplomatic and residential district of Dhaka. Dr. Basu brings clinical expertise from the Tata Memorial Hospital in Mumbai, India, while chief medical physicist Mr. Karthick Raj Mani previously worked at the SGPGI in Lucknow, India.

"We are honoured to be associated with this wonderful new facility serving the people of Bangladesh," says Rolf Staehelin, Varian's international marketing director. "There are huge challenges facing cancer treatment in Bangladesh, with many patients travelling to Singapore and India for treatment, and we hope RapidArc at United will play its part in starting to address the country's extensive cancer burden."

According to recently published reports there are currently over one million people with cancer in Bangladesh, with approximately 200,000 new cases being reported annually and approximately 150,000 deaths associated with the disease.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,300 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com.*Published papers on this topic:Kjaer-Kristoffersen F., Ohlhues L., Medin J., Korreman S. RapidArc volumetric modulated therapy planning for prostate cancer patients. Acta Oncology. 2008:48 (2): 227-32Using Volumetric Modulated Arc Therapy. International Journal of RadiationOncology*Biology*Physics 1 Sept. 2009: 253-259. ScienceDirect. Web. 26 Oct. 2009Palma D., Vollans E., James K., Nakano S., Moiseenko V, Shaffer R., McKenzie M., Morris J.,Otto K. Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: ComparisonWith Intensity-Modulated Radiotherapy and Three-Dimensional Conformal RadiotherapyInternational Journal of Radiation Oncology*Biology*Physics, Volume 72, Issue 4, 15 November2008, Pages 996-1001Zhang P., Happersett L., Hunt M., Jackson A., Zelefsky M., Mageras G. Volumetric ModulatedArc Therapy: Planning and Evaluation for Prostate Cancer Cases. International Journal ofradiation Oncology*Biology* Physics, [Epub ahead of print]  
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. 58% of Physicians Support FDA Move to Pull Breast Cancer Indication from Avastin
2. Missouri Baptist Medical Center - Only Non-Teaching Hospital in Region to Offer Colorectal Cancer Patients Robotic Surgery
3. UNC Selects MedAssurant to Support Investigation of Relationship Between Insulin and Cancer Development
4. Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine
5. Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
6. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
7. Triple Negative Cancer Research Could Benefit All Breast Cancer Patients
8. Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
9. Avantra Biosciences Launches Multiplex System for Faster, Easier Quantification of Cancer Protein Biomarkers
10. Reportlinker Adds The 2011 Cancer Diagnostics Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers
11. Reportlinker Adds The 2011 Japanese Cancer Diagnostics Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of ... Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, ... ... at US$ 7,167.6 Mn in 2015, and is expected to ... of 5.6% from 2016 to 2024. The ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), ... Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Executive Officer of the Company is scheduled to present on Tuesday, ... and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article ... of ancient teeth, which reveal a great deal about prehistoric ice-age dental practitioners and ... may have been used to remove decayed dental matter, and that teeth were then ...
(Date:4/21/2017)... ... 21, 2017 , ... Chicago plastic surgeon, Dr. Anil R. Shah, MD ... a benign bony lump located on the forehead usually attributed to a facial fracture. ... and pain. Dr. Shah has discovered an approach that is minimally invasive. He is ...
(Date:4/21/2017)... ... ... Dudnyk has announced the launch of its new brand identity, called The ... specialty and orphan brands can only be achieved when the needs and beliefs of ... at the heart of a true partnership between our agency and our clients to ...
(Date:4/21/2017)... ... ... The Hong Kong Polytechnic University (PolyU) launched today the University Research Facility ... Hong Kong to support teaching, learning and research. It is also the largest research ... Hong Kong. , With an area of 620 square metres and more than ...
(Date:4/21/2017)... ... April 21, 2017 , ... Airway Management, the medical device ... highly regarded and well renowned Asian distributor, Discovery Sleep. The agreement ... Pillow Mask, and will stabilize and strengthen Airway’s presence with a dedicated, reputable ...
Breaking Medicine News(10 mins):